NASDAQ: JUNS
Jupiter Neurosciences Inc Earnings Dates, Reports, Calls

Jupiter Neurosciences earnings were -$3.3M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest JUNS earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$1.5M, up 0.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, JUNS reported annual earnings of -$2.4M, with -49% growth.

JUNS earnings history

Current Revenue
$0.0
Current Earnings
-$3.3M
Current Profit Margin
0%

JUNS Return on Equity

Insufficient data to display

JUNS undefined

Current Company
-117.1%
Current Industry
-2.5%
JUNS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when JUNS announces earnings.

JUNS undefined

Current Company
-102.14%
Current Industry
5.8%

JUNS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
JUNSN/A-$3.33MN/A-$0.11
KZR-$76.06M-$78.63MN/A-$10.82
FBLG-$7.05M-$7.67MN/A-$0.21
PULM-$12.03M-$12.19MN/A-$3.35
INKT-$9.53M-$9.74MN/A-$2.56

Jupiter Neurosciences Earnings Reports & History FAQ

What were Jupiter Neurosciences's earnings last quarter?

Jupiter Neurosciences (NASDAQ: JUNS) reported Q1 2025 earnings per share (EPS) of -$0.05, up 150% year over year. Total JUNS earnings for the quarter were -$1.53 million. In the same quarter last year, Jupiter Neurosciences's earnings per share (EPS) was -$0.02.

If you're new to stock investing, here's how to buy Jupiter Neurosciences stock.

Is Jupiter Neurosciences profitable or losing money?

As of the last Jupiter Neurosciences earnings report, Jupiter Neurosciences is currently losing money. Jupiter Neurosciences's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$3.33 million, a 9.16% decrease year over year.

What was JUNS's earnings growth in the past year?

As of Jupiter Neurosciences's earnings date in Q2 2025, Jupiter Neurosciences's earnings has grown year over year. JUNS earnings in the past year totalled -$3.33 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.